ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis
This trial is active, not recruiting.
|Sponsor||Turku University Hospital|
|Collaborator||University of Turku|
|Start date||October 2005|
|Trial size||230 participants|
|Trial identifier||NCT01301885, ENDOMET-231/2004|
Endometriosis is a chronic disease characterized by the presence of functional endometrial glands and stroma in ectopic locations outside the uterine cavity. The ectopic endometrial tissue responds to estradiol and other hormones similarly to the normal endometrium. Endometriosis is one of the most common benign gynecological conditions, as many as 5-10% of women in the reproductive age may be affected. In addition to pain which may be severe, subfertility is one of the typical problems associated with endometriosis and may be present in up to 40% of those affected. There is lack of a clear correlation between severity of pain and degree of compromised fertility. Different modes of treatment exist. Hormonal treatments are based on the suppression of estrogenic action on endometriosis as well as the endometrium. Unfortunately, discontinuation of the hormonal treatment typically results in a rapid recurrence of the disease. Surgery may alleviate the symptom for different lengths of time, however, curative treatment frequently involves hysterectomy with bilateral oophorectomy. In order to escape this radical treatment, new targeted therapy in the form of novel pharmacological agents would be of crucial importance. Presently, endometriosis can be reliably diagnosed only by laparoscopy. Since this is an invasive surgical procedure, new diagnostic tools would be warmly welcomed. Furthermore, as the progression of the disease is presently impossible to predict, new markers for the "malignancy" of each case are desperately needed.
The aim of the investigators research is to identify expression of endometriosis specific RNAs/proteins. Evaluation of expression profiles in samples of endometriosis and endometrium of patients with careful clinical and surgical classification of endometriosis as well as healthy control women should initially enable to identify novel targets for new therapies and biomarkers. Furthermore, combined with an adequate follow up, the study should enable for example to identify markers for endometriosis associated infertility as well as cases where the disease progresses very rapidly. Different forms of effective treatment may thereafter be designed following the identification of such factors.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Helsinki, Finland||Dept of Obstetrics and Gynecology, Helsinki University Hospital||no longer recruiting|
|Joensuu, Finland||Dept of Obstetrics and Gynecology, North Carelia Central Hospital||no longer recruiting|
|Lahti, Finland||Dept of Obstetrics and Gynecology, Päijät-Häme Central Hospital||no longer recruiting|
|Turku, Finland||Dept of Obstetrics and Gynecology, Turku University Central Hospital||no longer recruiting|
|Observational model||case control|
Women (19-38 years of age) with surgically confirmed endometriosis
Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
Female participants from 19 years up to 48 years old.
- study group: surgically and pathologically verified endometriosis
- control group: existence of endometriosis ruled out in laparoscopy
- no other significant disease or medication for other diseases
|Official title||Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications|
|Principal investigator||Antti Perheentupa, MD, PhD|
Call for more information